Table 1.
Demographic and clinical characteristics of MS patients treated with teriflunomide or dimethyl fumarate at baseline.
| TFM (n = 60) | DMF (n = 60) | p-Value | |
|---|---|---|---|
| Age, mean (SD) | 50.9 (8) | 50.8 (7.5) | 0.879 |
| Age onset, mean (SD) | 33.5 (10.2) | 33.8 (9.7) | 0.869 |
| Disease duration, mean (SD) | 16.3 (8.6) | 15.6 (9.6) | 0.674 |
| Sex, n (%) | 0.820 | ||
| Female | 47 (78.3) | 49 (81.7) | |
| Male | 13 (21.7) | 11 (18.3) | |
| BMI, mean (SD) | 27.2 (5.9) | 28.8 (6.1) | 0.171 |
| Race, n (%) | 0.606 | ||
| Caucasian | 45 (75) | 47 (78.3) | |
| African-American | 7 (11.7) | 10 (16.7) | |
| Hispanic | 8 (13.3) | 3 (5) | |
| EDSS at baseline, median (IQR) | 3.0 (2.5–3.5) | 2.75 (2.0–3.5) | 0.377 |
| Relapse rate in previous 12 months, mean (SD) | 0.28 (0.49) | 0.38 (0.66) | 0.351 |
| Relapse rate in previous 24 months, mean (SD) | 0.38 (0.66) | 0.35 (0.63) | 0.779 |
| DMT previous 12 months, n (%) | 0.144 | ||
| Interferon-beta 1a | 18 (30) | 23 (38.3) | |
| Glatiramer acetate | 9 (15) | 9 (15) | |
| Natalizumab | 15 (25) | 11 (18.3) | |
| Oral | 4 (6.7) | 0 (0) | |
| Other | 0 (0) | 3 (5) | |
| No treatment | 14 (23.3) | 14 (23.3) |
MS-multiple sclerosis; TFM-teriflunomide; DMF-dimethyl fumarate; BMI-body mass index; EDSS-Expanded Disability Status Scale; IQR-interquartile range; DMT-disease-modifying therapy. Oral treatment of selected patients treated previously with fingolimod. Other medications included intravenous immunoglobulin (n = 2) and mitoxantrone (n = 2). p-values derived from chi-squared test, Student’s t-test, and Mann–Whitney rank-sum test.